Immunomodulatory effects of histone deacetylase inhibitors

P. V. Licciardi, K. Ververis, M. L. Tang, A. El-Osta, T. C. Karagiannis

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics. The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce celldeath, apoptosis and differentiation in malignant and transformed cells. This provides the basis for the clinical potential of HDACi in cancer therapy. Currently two compounds, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza™) and depsipeptide (Romidepsin, Istodax™) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma. Apart from clinical application in oncology, HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria. Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review. We review the antiinflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes. The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation versus tolerance are also discussed.
Original languageEnglish
Pages (from-to)640-647
Number of pages8
JournalCurrent Molecular Medicine
Volume13
Issue number4
DOIs
Publication statusPublished - 2013

Keywords

  • Chromatin modifications
  • histone acetylation
  • histone deacetylase inhibitor
  • Trichostatin A
  • HDAC11
  • immune system
  • immunomodulation

Cite this

Licciardi, P. V. ; Ververis, K. ; Tang, M. L. ; El-Osta, A. ; Karagiannis, T. C. / Immunomodulatory effects of histone deacetylase inhibitors. In: Current Molecular Medicine. 2013 ; Vol. 13, No. 4. pp. 640-647.
@article{50549bf5ba39426a85d28d22d1301858,
title = "Immunomodulatory effects of histone deacetylase inhibitors",
abstract = "Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics. The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce celldeath, apoptosis and differentiation in malignant and transformed cells. This provides the basis for the clinical potential of HDACi in cancer therapy. Currently two compounds, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza™) and depsipeptide (Romidepsin, Istodax™) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma. Apart from clinical application in oncology, HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria. Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review. We review the antiinflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes. The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation versus tolerance are also discussed.",
keywords = "Chromatin modifications, histone acetylation, histone deacetylase inhibitor, Trichostatin A, HDAC11, immune system, immunomodulation",
author = "Licciardi, {P. V.} and K. Ververis and Tang, {M. L.} and A. El-Osta and Karagiannis, {T. C.}",
year = "2013",
doi = "10.2174/1566524011313040013",
language = "English",
volume = "13",
pages = "640--647",
journal = "Current Molecular Medicine",
issn = "1566-5240",
publisher = "Bentham Science Publishers",
number = "4",

}

Immunomodulatory effects of histone deacetylase inhibitors. / Licciardi, P. V.; Ververis, K.; Tang, M. L.; El-Osta, A.; Karagiannis, T. C.

In: Current Molecular Medicine, Vol. 13, No. 4, 2013, p. 640-647.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Immunomodulatory effects of histone deacetylase inhibitors

AU - Licciardi, P. V.

AU - Ververis, K.

AU - Tang, M. L.

AU - El-Osta, A.

AU - Karagiannis, T. C.

PY - 2013

Y1 - 2013

N2 - Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics. The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce celldeath, apoptosis and differentiation in malignant and transformed cells. This provides the basis for the clinical potential of HDACi in cancer therapy. Currently two compounds, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza™) and depsipeptide (Romidepsin, Istodax™) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma. Apart from clinical application in oncology, HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria. Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review. We review the antiinflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes. The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation versus tolerance are also discussed.

AB - Histone deacetylase inhibitors (HDACi) have emerged as a new generation of anticancer therapeutics. The classical broad-spectrum HDACi typically alter the cell cycle distribution and induce celldeath, apoptosis and differentiation in malignant and transformed cells. This provides the basis for the clinical potential of HDACi in cancer therapy. Currently two compounds, suberoylanilide hydroxamic acid (SAHA, Vorinostat, Zolinza™) and depsipeptide (Romidepsin, Istodax™) have been approved for by the US Food and Drug Administration for the treatment of refractory cutaneous T-cell lymphoma. Apart from clinical application in oncology, HDACi have also been investigated as potential therapeutics for various pathologies including those of the central nervous system (such as Huntington's disease and multiple sclerosis), cardiac conditions (particularly hypertrophy), arthritis and malaria. Further, evidence is accumulating for potent immunomodulatory effects of classical HDACi which is the focus of this review. We review the antiinflammatory effects of HDACi and in particular findings implicating regulation of the innate and adaptive immune systems by HDAC enzymes. The recent findings highlighting the immunomodulatory function of HDAC11 which relates to balancing immune activation versus tolerance are also discussed.

KW - Chromatin modifications

KW - histone acetylation

KW - histone deacetylase inhibitor

KW - Trichostatin A

KW - HDAC11

KW - immune system

KW - immunomodulation

UR - http://www.ncbi.nlm.nih.gov/pubmed/23061676

U2 - 10.2174/1566524011313040013

DO - 10.2174/1566524011313040013

M3 - Article

VL - 13

SP - 640

EP - 647

JO - Current Molecular Medicine

JF - Current Molecular Medicine

SN - 1566-5240

IS - 4

ER -